Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 342Other hematologic neoplasm 299Plasma cell 114Sarcoma 111Myeloid 101CNS 100Breast 92Genitourinary 59Gynecologic 52Classical hematology 41Dermatologic 38Other solid neoplasm 25Thoracic 24Gastrointestinal 20Head & Neck 18Endocrine 7Other neoplasm 2NET 2Tumor-Agnostic 1Other 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Blood Specimen Collection 28Radiosurgery 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Filgrastim × Tumor-Agnostic × Clear all
NCT01057264 2015-11-18

HAI Abraxane With Gemcitabine and Bevacizumab

M.D. Anderson Cancer Center

Phase 1 Completed
78 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡